These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 28685513)

  • 1. Effects of Vildagliptin or Pioglitazone on Glycemic Variability and Oxidative Stress in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy: A 16-Week, Randomised, Open Label, Pilot Study.
    Kim NH; Kim DL; Kim KJ; Kim NH; Choi KM; Baik SH; Kim SG
    Endocrinol Metab (Seoul); 2017 Jun; 32(2):241-247. PubMed ID: 28685513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Vildagliptin and Pioglitazone in Korean Patients with Type 2 Diabetes Inadequately Controlled with Metformin.
    Kim JH; Kim SS; Baek HS; Lee IK; Chung DJ; Sohn HS; Bae HY; Kim MK; Park JH; Choi YS; Kim YI; Hahm JR; Lee CW; Jo SR; Park MK; Lee KJ; Kim IJ
    Diabetes Metab J; 2016 Jun; 40(3):230-9. PubMed ID: 27098505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Acarbose on Glycemic Variability in Patients with Poorly Controlled Type 2 Diabetes Mellitus Receiving Stable Background Therapy: A Placebo-Controlled Trial.
    Derosa G; Franzetti I; Querci F; D'Angelo A; Maffioli P
    Pharmacotherapy; 2015 Nov; 35(11):983-90. PubMed ID: 26598090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of a Fixed-Dose Combination of Vildagliptin and Pioglitazone in Indian Patients With Type 2 Diabetes Mellitus: A Randomized, Open-Label, Comparative, Phase III Study.
    Erande S; Mukhopadhyay J; Dange A; Deogaonkar A; Birla A; Doshi C; Revankar S; B SS; Kumar N; Kadam PV
    Cureus; 2023 Sep; 15(9):e44548. PubMed ID: 37795066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study.
    Guerci B; Monnier L; Serusclat P; Petit C; Valensi P; Huet D; Raccah D; Colette C; Quéré S; Dejager S
    Diabetes Metab; 2012 Oct; 38(4):359-66. PubMed ID: 22809630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial.
    Umpierrez G; Issa M; Vlajnic A
    Curr Med Res Opin; 2006 Apr; 22(4):751-9. PubMed ID: 16684436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study.
    Bolli G; Dotta F; Rochotte E; Cohen SE
    Diabetes Obes Metab; 2008 Jan; 10(1):82-90. PubMed ID: 18034842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient preference and tolerability of a DPP-4 inhibitor versus a GLP-1 analog in patients with type 2 diabetes mellitus inadequately controlled with metformin: a 24-week, randomized, multicenter, crossover study.
    Lüdemann J; Dütting ED; Dworak M
    Ther Adv Endocrinol Metab; 2015 Aug; 6(4):141-8. PubMed ID: 26301063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes.
    Rosenstock J; Kim SW; Baron MA; Camisasca RP; Cressier F; Couturier A; Dejager S
    Diabetes Obes Metab; 2007 Mar; 9(2):175-85. PubMed ID: 17300593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study.
    Kendall DM; Rubin CJ; Mohideen P; Ledeine JM; Belder R; Gross J; Norwood P; O'Mahony M; Sall K; Sloan G; Roberts A; Fiedorek FT; DeFronzo RA
    Diabetes Care; 2006 May; 29(5):1016-23. PubMed ID: 16644631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vildagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus.
    Profit L; Chrisp P; Nadin C
    Core Evid; 2008 Jun; 3(1):13-30. PubMed ID: 20694081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Glycemic variability and oxidative stress in children, with type 1 diabetes attending a summer camp].
    Colomo N; Tapia MJ; Vallejo MR; García-Torres F; Rubio-Martín E; Caballero FF; Jiménez JM; Pelaez MJ; Gómez AM; Sánchez I; López-Siguero JP; Soriguer F; Ruiz de Adana MS
    An Pediatr (Barc); 2014 Sep; 81(3):174-80. PubMed ID: 24290964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 16-week study to compare the effect of vildagliptin versus gliclazide on postprandial lipoprotein concentrations and oxidative stress in patients with type 2 diabetes inadequately controlled with metformin monotherapy.
    Hissa MR; Cavalcante LL; Guimarães SB; Hissa MN
    Diabetol Metab Syndr; 2015; 7():62. PubMed ID: 26170902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin.
    Bosi E; Camisasca RP; Collober C; Rochotte E; Garber AJ
    Diabetes Care; 2007 Apr; 30(4):890-5. PubMed ID: 17277036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effects of vildagliptin and sitagliptin determined by continuous glucose monitoring in patients with type 2 diabetes mellitus.
    Koyanagawa N; Miyoshi H; Ono K; Nakamura A; Cho KY; Yamamoto K; Takano Y; Dan-Noura M; Atsumi T
    Endocr J; 2016 Aug; 63(8):747-53. PubMed ID: 27321385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Rosenstock J; Brazg R; Andryuk PJ; Lu K; Stein P;
    Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Randomized Controlled Trial of Vildagliptin Versus Alogliptin: Effective Switch From Sitagliptin in Patients With Type 2 Diabetes.
    Shigematsu E; Yamakawa T; Oba MS; Suzuki J; Nagakura J; Kadonosono K; Terauchi Y
    J Clin Med Res; 2017 Jul; 9(7):567-572. PubMed ID: 28611856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of Vildagliptin and Pioglitazone in Experimental Type 2 Diabetes in Male Rats.
    Refaat R; Sakr A; Salama M; El Sarha A
    Drug Dev Res; 2016 Sep; 77(6):300-9. PubMed ID: 27520857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vildagliptin: a review of its use in the management of type 2 diabetes mellitus.
    Croxtall JD; Keam SJ
    Drugs; 2008; 68(16):2387-409. PubMed ID: 18973400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti oxidant potential of Metformin and Pioglitazone in Type 2 Diabetes Mellitus: Beyond their anti glycemic effect.
    Singh RK; Gupta B; Tripathi K; Singh SK
    Diabetes Metab Syndr; 2016; 10(2):102-4. PubMed ID: 26341927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.